AR101757A1 - ANTI-MFI2 ANTIBODIES AND METHODS OF USE - Google Patents

ANTI-MFI2 ANTIBODIES AND METHODS OF USE

Info

Publication number
AR101757A1
AR101757A1 ARP150102824A ARP150102824A AR101757A1 AR 101757 A1 AR101757 A1 AR 101757A1 AR P150102824 A ARP150102824 A AR P150102824A AR P150102824 A ARP150102824 A AR P150102824A AR 101757 A1 AR101757 A1 AR 101757A1
Authority
AR
Argentina
Prior art keywords
methods
antibodies
mfi2 antibodies
drug conjugates
antibody drug
Prior art date
Application number
ARP150102824A
Other languages
Spanish (es)
Inventor
Boontanrart Mandy
Karsunky Holger
Saunders Laura
Williams Samuel
Original Assignee
Stemcentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemcentrx Inc filed Critical Stemcentrx Inc
Publication of AR101757A1 publication Critical patent/AR101757A1/en

Links

Abstract

Anticuerpos anti-MF12 y conjugados de droga anticuerpo, y los métodos para usar tales anticuerpos anti-MF12 y conjugados de fármaco anticuerpo para tratar el cáncer. Ácido nucleico, vector, célula huésped, composición farmacéutica.Anti-MF12 antibodies and antibody drug conjugates, and methods for using such anti-MF12 antibodies and antibody drug conjugates to treat cancer. Nucleic acid, vector, host cell, pharmaceutical composition.

ARP150102824A 2014-09-05 2015-09-03 ANTI-MFI2 ANTIBODIES AND METHODS OF USE AR101757A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462046610P 2014-09-05 2014-09-05

Publications (1)

Publication Number Publication Date
AR101757A1 true AR101757A1 (en) 2017-01-11

Family

ID=58698690

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102824A AR101757A1 (en) 2014-09-05 2015-09-03 ANTI-MFI2 ANTIBODIES AND METHODS OF USE

Country Status (1)

Country Link
AR (1) AR101757A1 (en)

Similar Documents

Publication Publication Date Title
CL2016000468A1 (en) Anti-dll3 conjugates (ligand3 delta type) manipulated and methods of use.
CO2018001624A2 (en) Anti-dll3-antibody antibody conjugates and methods of use
AR101845A1 (en) ANTI-HER2 AND IMMUNOCUSED ANTIBODIES
DOP2017000052A (en) NEW ANTI-MFI2 ANTIBODIES AND METHODS OF USE
PE20191403A1 (en) ANTI-OX40 ANTIBODIES AND THEIR USES
EA201790248A1 (en) MEDIA-ANTIBODY COMPOSITIONS AND METHODS FOR THEIR RECEIVING AND APPLICATION
BR112018074463A2 (en) anti-tim-3 antibodies and methods of use.
BR112017025564A2 (en) anti-ctla-4 antibodies and methods of use
AR093377A1 (en) ANTI-NOTCH ANTIBODIES AND ANTIBODY-FARMACO CONJUGATES
AR090903A1 (en) ANTI-PMEL ANTIBODIES AND IMMUNOCADES17
BR112019012343A2 (en) il-11ra antibodies
AR099465A1 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
BR112016010706A2 (en) bispecific antibody, pharmaceutical composition, use of bispecific antibody, nucleic acid sequence, expression vector, host cell and method of producing an antibody
EA201791253A1 (en) ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
CL2015002357A1 (en) New antibody conjugates and uses thereof
EA201692425A1 (en) MODIFIED BIOPOLYMERS AND METHODS OF THEIR PRODUCTION AND USE
ECSP17011657A (en) DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES
MX2018006249A (en) Novel anti-emr2 antibodies and methods of use.
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
UY35835A (en) Specific antibodies to FcRn.
EA201790773A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES
TR201820050T4 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors.
MX2018007817A (en) Novel anti-mmp16 antibodies and methods of use.
CL2018002848A1 (en) Liquid phosphoplatin formulations
MX2018007818A (en) Novel anti-upk1b antibodies and methods of use.

Legal Events

Date Code Title Description
FB Suspension of granting procedure